European Archives - Page 30 of 1195 - European Medical Journal

Urine Tumour DNA Could Guide Therapeutic Decisions in Bladder Cancer

Profiling urine tumour DNA at baseline and after 3 months of treatment could identify whether patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer might not benefit from systemic immunotherapy.

Chronic Inflammation Linked to Increased Affective Disorders

Chronic exposure to systemic inflammation may be associated to a greater risk of affective disorders.

Can Post-Treatment MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy?

Pathologic complete response was accurately predicted by post-treatment MRI in patients with early triple-negative breast cancer having undergone neoadjuvant chemoimmunotherapy.

Parkinson’s Dementia Trial: Does Ambroxol Work Biologically and Clinically?

Ambroxol increased enzyme levels in Parkinson’s dementia patients, but showed no cognitive benefit in a year-long trial.

Pharma seized the spotlight at Cannes Lions – here's why

In a departure from years past, Cannes Lions 2025 saved a sizable percentage of their praise for companies in the pharma space.

Hyperbaric Oxygen Therapy Leads Diabetic Foot Ulcer Treatment Rankings in New Meta-Analysis

Hyperbaric oxygen therapy ranks highest for healing diabetic foot ulcers but may raise amputation risk, new network meta-analysis reveals.

Study Links Bifidobacterium Deficit in Infants in the USA to Gut Dysbiosis

One in four U.S. infants lacks Bifidobacterium, a key gut microbe essential for immune and metabolic health.

Head-to-Head Trial Supports Cheaper Hepatitis C Drug

Beyond the head-to-head comparison, the study also explored innovative strategies to simplify or shorten treatment.

Illustration of scientific tools

New report calls for faster R&D for rare diseases

A report has found that while many in the UK live with rare diseases, systemic failures continue to restrict progress in treatment.

GSK’s Matt Mortimer-Ryan on behaviour-led pharma marketing

Matt Mortimer Ryan, GSK, discusses how understanding patients’ emotional drivers can unlock more impactful pharma marketing campaigns.